Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|December 9, 2016
Potential for Glembatumumab Vedotin in TNBC
Author(s)Linda T. Vahdat, MD, PhD
Linda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5